TriangleParticipants with esophagastric adenocarcinoma will be treated with an intraperitoneal infusion of different doses of autologous T cells that have been genetically modified ex vivo to express the M28z1XXPD1DNR CAR. The CAR T cells will be manufactured in MSK's Center for Cell Engineering.
M28z1XXPD1DNR CAR
Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
- RegistryNCT06623396
- PhasePhase 1
- StatusRecruiting
- ConditionMesothelin-Expressing Tumors
- SponsorMemorial Sloan Kettering Cancer Center
The drug
What is being tested.
The study
How the trial runs.
Participants will have a sample of their white blood cells, called T cells, collected using a procedure called leukapheresis. The collected T cells will be sent to a laboratory at Memorial Sloan Kettering to be changed (modified) to become MSLN-targeted CAR T cells, the CAR T-cell therapy that participants will receive during the study. Participant study therapy will take about 3-4 weeks.
Eligibility
Who the study is looking for.
- Diagnosis of pathologically confirmed EG adenocarcinoma
- Diagnosis of metastatic or recurrent disease
- ECOG performance status of 0-1
- Life expectancy of ≥4 months
- Inclusion Criteria for Leukapheresis:
- Written informed consent for the study (from participant)
Inclusion criteria as written on the registry, trimmed. The full list, with exclusions, is on the live record.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.